+Compare
EDSA
Stock ticker: NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
17.97M

EDSA Edesa Biotech Forecast, Technical & Fundamental Analysis

a biopharmaceutical company, which focuses on acquiring, developing and commercializing clinical stage drugs for dermatological and gastrointestinal indications with clear unmet medical needs.

Industry Biotechnology
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for EDSA with price predictions
08:00 PM EDT Sep 21, 2023

EDSA saw its Stochastic Oscillator recovers from the overbought zone

The Stochastic Oscillator for EDSA moved out of overbought territory on September 20, 2023. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 37 similar instances where the indicator exited the overbought zone. In of the 37 cases the stock moved lower. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 22, 2023. You may want to consider selling the stock, shorting the stock, or exploring put options on EDSA as a result. In of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for EDSA turned negative on September 21, 2023. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at .

EDSA moved below its 50-day moving average on September 22, 2023 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where EDSA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

EDSA broke above its upper Bollinger Band on September 15, 2023. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where EDSA advanced for three days, in of 241 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 80 cases where EDSA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. EDSA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.310) is normal, around the industry mean (22.634). P/E Ratio (0.000) is within average values for comparable stocks, (131.508). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.085). Dividend Yield (0.000) settles around the average of (0.034) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (305.056).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EDSA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Novavax (NASDAQ:NVAX), Sorrento Therapeutics (OTC:SRNEQ).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.18B. The market cap for tickers in the group ranges from 402 to 410.28B. NVO holds the highest valuation in this group at 410.28B. The lowest valued company is PNEXF at 402.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -3%. For the same Industry, the average monthly price growth was 22%, and the average quarterly price growth was 34%. SKYED experienced the highest price growth at 81%, while SEEL experienced the biggest fall at -82%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -27%. For the same stocks of the Industry, the average monthly volume growth was 80% and the average quarterly volume growth was 85%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 87
Price Growth Rating: 69
SMR Rating: 93
Profit Risk Rating: 95
Seasonality Score: -26 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I. Advisor
published Earnings

EDSA is expected to report earnings to rise 56.70% to -15 cents per share on December 13

Edesa Biotech EDSA Stock Earnings Reports
Q3'23
Est.
$-0.16
Q2'23
Beat
by $0.06
Q1'23
Est.
$-0.12
Q4'22
Beat
by $0.05
Q3'22
Beat
by $0.03
The last earnings report on August 11 showed earnings per share of -10 cents, beating the estimate of -15 cents. With 8.34K shares outstanding, the current market capitalization sits at 17.97M.
A.I. Advisor
published General Information

General Information

a biopharmaceutical company, which focuses on acquiring, developing and commercializing clinical stage drugs for dermatological and gastrointestinal indications with clear unmet medical needs.

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
100 Spy Court
Phone
+1 289 800-9600
Employees
16
Web
https://www.edesabiotech.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ALGN298.56-1.72
-0.57%
Align Technology
TG5.18-0.04
-0.77%
Tredegar Corp
CNS61.23-0.57
-0.92%
Cohen & Steers
BRCC3.64-0.32
-8.08%
BRC
RVYL3.26-0.44
-11.89%
Ryvyl

EDSA and

Correlation & Price change

A.I.dvisor tells us that EDSA and SNPX have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that EDSA and SNPX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EDSA
1D Price
Change %
EDSA100%
-0.90%
SNPX - EDSA
33%
Poorly correlated
+30.17%
ORMP - EDSA
32%
Poorly correlated
-1.14%
RNAZ - EDSA
31%
Poorly correlated
-4.72%
FBIO - EDSA
30%
Poorly correlated
-3.28%
MDGL - EDSA
30%
Poorly correlated
-3.87%
More

Groups containing EDSA

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EDSA
1D Price
Change %
EDSA100%
-0.90%
north america
(undefined stocks)
20%
Poorly correlated
+0.15%